Results 21 to 30 of about 19,567,220 (299)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. [PDF]

Cancer Manag Res, 2021
Purpose Rising melanoma incidences lead to an increasing need for individual therapy strategies in old patients. Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, approved for the local treatment of unresectable metastatic melanoma ...
Kleemann J, Jäger M, Valesky E, Kippenberger S, Kaufmann R, Meissner M.   +5 more
europepmc   +2 more sources

Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report. [PDF]

Br J Dermatol, 2019
Talimogene laherparepvec (T‐VEC) is a intralesional oncolytic virotherapy, licensed in the European Union for locoregional advanced melanoma of American Joint Committee on Cancer stages IIIB, IIIC and IVM1a.
Ressler J, Silmbrod R, Stepan A, Tuchmann F, Cicha A, Uyanik-Ünal K, Hoeller C.   +6 more
europepmc   +2 more sources

High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a) [PDF]

International Journal of Cancer, 2019
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label).
V. Franke, D. Berger, W. Klop, B. Hiel, B. Wiel, S. Meulen, M. Wouters, W. Houdt, A. V. Akkooi   +8 more
semanticscholar   +3 more sources

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. [PDF]

J Immunother Cancer, 2018
BackgroundImmunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up.
Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst BA, Saenger YM.   +8 more
europepmc   +2 more sources

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734 [PDF]

Viruses
NUT carcinoma (NC) is a rare exceptionally aggressive malignancy, defined by NUTM1 gene translocations, most commonly generating a BRD4::NUTM1 fusion that results in a poor prognosis and limited therapeutic options. Oncolytic virotherapy has emerged as a
Fiona D. Nitschke, Julia Beil, Irina Smirnow, Andrea Schenk, Mary E. Carter, Ulrich M. Lauer, Linus D. Kloker   +6 more
doaj   +2 more sources

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) [PDF]

Nature Communications
This single-arm, phase II, preoperative window-of-opportunity trial (ClinicalTrials.gov Identifier: NCT03802604) investigated the efficacy and safety of talimogene laherparepvec (T-VEC), an oncolytic virus, with atezolizumab, an anti–PD-L1 antibody, in ...
Tomás Pascual, Maria Vidal, Juan M. Cejalvo, Estela Vega, Esther Sanfeliu, Guillermo Villacampa, Sergi Ganau, Ana María Julve Parreño, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Elia Seguí, Fara Brasó-Maristanty, Luis de la Cruz-Merino, Manel Juan, Patricia Galván, Xavier Gonzàlez-Farré, Samyukta Chillara, Patricia Villagrasa, Adam D. Pfefferle, Constandina E. O’Connell, Juan M. Ferrero-Cafiero, Mafalda Oliveira, Charles M. Perou, Aleix Prat   +25 more
doaj   +2 more sources

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness ...
Shailender Bhatia, Paul T Nghiem, George Ansstas, Song Y Park, Coley Doolittle-Amieva, Evan T Hall, Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, David Y Chen   +10 more
doaj   +2 more sources

The Transformation Matrices of vec A to vec A^T for Diagonal Matrix [PDF]

, 2023
This study aims to discusses the transformation matrices of vec A to vec A^T for diagonal matrix. The matrix used is a 4 x 4 diagonal matrix assuming that two pairs of elements are located on the main diagonal with the same value.
Yulianti, Lyra, Yanita, Yanita, Ahmad, Rusdi   +2 more
core   +2 more sources

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

Frontiers in Molecular Biosciences, 2022
Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes Simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF).
Howard L. Kaufman, Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice   +3 more
doaj   +1 more source

Image_1_Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.tif [PDF]

, 2021
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated ...
Inès Dufait (5813792), Jens Tijtgat (11617399), Julia Katharina Schwarze (11617405), Jolien De Munck (11617402), Joeri L. Aerts (4814685), Ivan Van Riet (480852), Bart Neyns (88629), Sandra Tuyaerts (6747536), Karine Breckpot (188779), Lorenzo Franceschini (2941200)   +9 more
core   +1 more source